Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 14Breast 5Other hematologic neoplasm 3Sarcoma 2Gynecologic 2Plasma cell 1Myeloid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Endometrial Neoplasms 2Ovarian Neoplasms 1Lymphoma, Follicular 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × copanlisib × Gynecologic × Clear all
NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 10 charts
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT04750941 2025-03-04

Study of Copanlisib and Ketogenic Diet

Columbia University

Phase 2 Terminated
1 enrolled 9 charts
GynecologicLymphoid

Lymphoma, Follicular, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡